Published in Gene Therapy Weekly, September 7th, 2006
Under the terms of the agreement, Neurologix has been granted a license for the use of the glutamic acid decarboxylase (GAD) 65 gene, a component of the core technology "NLX-P101" gene therapy used in its recently completed, landmark Phase I clinical trial.
The company will pay Diamyd a license issue fee of $500,000 and will pay annual maintenance fees beginning in January 2008. Upon commercialization of the Parkinson's product, the company will also make certain milestone and royalty payments.
"The company may now go forward with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.